BR9504791B1 - composto de polipeptìdeo e composição farmacêutica. - Google Patents

composto de polipeptìdeo e composição farmacêutica.

Info

Publication number
BR9504791B1
BR9504791B1 BRPI9504791-3A BR9504791A BR9504791B1 BR 9504791 B1 BR9504791 B1 BR 9504791B1 BR 9504791 A BR9504791 A BR 9504791A BR 9504791 B1 BR9504791 B1 BR 9504791B1
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
polypeptide compound
polypeptide
compound
pharmaceutical
Prior art date
Application number
BRPI9504791-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9504791A (pt
Inventor
Hidenori Ohki
Masaki Tomishima
Akira Yamada
Hisashi Takasugi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9504791(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed filed Critical
Publication of BR9504791A publication Critical patent/BR9504791A/pt
Publication of BR9504791B1 publication Critical patent/BR9504791B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI9504791-3A 1994-10-07 1995-10-06 composto de polipeptìdeo e composição farmacêutica. BR9504791B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound

Publications (2)

Publication Number Publication Date
BR9504791A BR9504791A (pt) 1996-10-22
BR9504791B1 true BR9504791B1 (pt) 2010-10-05

Family

ID=26305774

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9504791-3A BR9504791B1 (pt) 1994-10-07 1995-10-06 composto de polipeptìdeo e composição farmacêutica.
BRPI9504791A BRPI9504791B8 (pt) 1994-10-07 1995-10-06 composto de polipeptídeo e composição farmacêutica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI9504791A BRPI9504791B8 (pt) 1994-10-07 1995-10-06 composto de polipeptídeo e composição farmacêutica.

Country Status (26)

Country Link
US (2) US6107458A (cg-RX-API-DMAC7.html)
EP (1) EP0788511B1 (cg-RX-API-DMAC7.html)
JP (2) JP2897427B2 (cg-RX-API-DMAC7.html)
KR (1) KR100353303B1 (cg-RX-API-DMAC7.html)
CN (1) CN1203089C (cg-RX-API-DMAC7.html)
AR (1) AR041770A1 (cg-RX-API-DMAC7.html)
AT (1) ATE229541T1 (cg-RX-API-DMAC7.html)
AU (1) AU696949B2 (cg-RX-API-DMAC7.html)
BR (2) BR9504791B1 (cg-RX-API-DMAC7.html)
CA (1) CA2202058C (cg-RX-API-DMAC7.html)
DE (2) DE122008000025I2 (cg-RX-API-DMAC7.html)
DK (1) DK0788511T3 (cg-RX-API-DMAC7.html)
ES (1) ES2187575T3 (cg-RX-API-DMAC7.html)
FI (1) FI119988B (cg-RX-API-DMAC7.html)
FR (1) FR08C0028I2 (cg-RX-API-DMAC7.html)
HU (1) HU228151B1 (cg-RX-API-DMAC7.html)
IL (1) IL115484A (cg-RX-API-DMAC7.html)
LU (1) LU91452I2 (cg-RX-API-DMAC7.html)
MX (1) MX9702531A (cg-RX-API-DMAC7.html)
NL (1) NL300352I2 (cg-RX-API-DMAC7.html)
NO (2) NO328483B1 (cg-RX-API-DMAC7.html)
OA (1) OA10475A (cg-RX-API-DMAC7.html)
PT (1) PT788511E (cg-RX-API-DMAC7.html)
RU (1) RU2165423C2 (cg-RX-API-DMAC7.html)
TR (1) TR199501229A2 (cg-RX-API-DMAC7.html)
WO (1) WO1996011210A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
US6291680B1 (en) * 1997-06-18 2001-09-18 Fujisawa Pharmaceutical Co., Ltd. Production process
CA2320416A1 (en) * 1998-02-09 1999-08-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
ES2251976T3 (es) * 1999-02-11 2006-05-16 Emisphere Technologies, Inc. Compuestos y composiciones de oxadiazol para aportar agentes activos.
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
CA2380176A1 (en) 1999-07-27 2001-02-01 Aventis Pharma Deutschland Gmbh Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
ATE452637T1 (de) 2001-01-29 2010-01-15 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US7199248B2 (en) 2002-08-08 2007-04-03 Astellas Pharma Inc. Process
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2005018743A1 (en) * 2003-07-22 2005-03-03 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
AU2004273029A1 (en) * 2003-09-05 2005-03-24 Merck & Co., Inc. Stationary phases and a purification process using the stationary phases
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
US20050261365A1 (en) * 2004-05-20 2005-11-24 The Scripps Research Institute Transthyretin stabilization
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
KR20070067165A (ko) * 2004-10-13 2007-06-27 피티씨 테라퓨틱스, 인크. 넌센스 변이 억제용 화합물, 및 이의 사용 방법
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
WO2007043401A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
PL2786992T3 (pl) 2007-08-13 2018-04-30 Monsanto Technology Llc Kompozycje i sposoby zwalczania nicieni
AU2008319977A1 (en) * 2007-10-29 2009-05-07 Astellas Pharma Inc. Polypeptide compound
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
CA2729212C (en) * 2008-06-24 2014-04-01 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) * 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
BR112013026420A2 (pt) 2011-04-20 2020-11-03 Xellia Pharmaceuticals Aps método de produção de um sal de micafungina farmaceuticamente aceitável
CN102775476B (zh) 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
EP2763971B1 (en) 2011-09-09 2016-06-08 Sandoz AG Preparation of micafungin intermediates
CN102659930B (zh) 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
CN102627689B (zh) 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
EP3150621A4 (en) * 2014-05-29 2017-12-27 Shanghai Techwell Biopharmaceutical Co., Ltd Composition of cyclic peptide compound, preparation method for same, and uses thereof
CN104861044B (zh) * 2014-05-29 2019-03-01 上海天伟生物制药有限公司 一种环肽类化合物的溶剂合物及其制备方法和用途
WO2016056023A2 (en) * 2014-10-07 2016-04-14 Alaparthi Lakshmi Prasad Intermediates and processes to prepare micafungin
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
FI3554474T3 (fi) 2016-12-16 2024-02-21 Baxter Int Mikafungiinikoostumuksia
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin
CN113087775B (zh) * 2018-05-31 2022-07-08 杭州中美华东制药有限公司 米卡芬净钠新晶型ii及其制备方法
WO2020013116A1 (ja) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Ｐｔｐ－１ｂ阻害剤およびその用途
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法
CN115785226A (zh) * 2021-09-09 2023-03-14 上海天伟生物制药有限公司 一种棘白菌素药物杂质及其制备、纯化方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1574603A1 (ru) * 1988-08-11 1990-06-30 Ивановский Химико-Технологический Институт Способ получени мезо-тетраарилоктаметилпорфиринов
FI912873A7 (fi) * 1990-06-18 1991-12-19 Fujisawa Pharmaceutical Co Uusi polypeptidiyhdiste ja menetelmä sen valmistamiseksi
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof

Also Published As

Publication number Publication date
CA2202058C (en) 2007-11-06
FR08C0028I1 (cg-RX-API-DMAC7.html) 2008-08-15
CN1168675A (zh) 1997-12-24
LU91452I2 (fr) 2008-08-04
HUT77736A (hu) 1998-07-28
NO971544D0 (no) 1997-04-04
KR970707150A (ko) 1997-12-01
JPH10507174A (ja) 1998-07-14
NO971544L (no) 1997-06-04
FI971397L (fi) 1997-05-27
ES2187575T3 (es) 2003-06-16
IL115484A (en) 2000-07-16
KR100353303B1 (ko) 2003-01-15
NL300352I1 (nl) 2008-08-01
NO2010016I2 (no) 2011-10-17
EP0788511A1 (en) 1997-08-13
DE122008000025I1 (de) 2008-08-21
NO2010016I1 (no) 2010-08-16
DE122008000025I2 (de) 2011-02-17
JP3518665B2 (ja) 2004-04-12
PT788511E (pt) 2003-04-30
ATE229541T1 (de) 2002-12-15
AU696949B2 (en) 1998-09-24
JP2897427B2 (ja) 1999-05-31
DE69529172D1 (de) 2003-01-23
US6107458A (en) 2000-08-22
JPH10324695A (ja) 1998-12-08
NO328483B1 (no) 2010-03-01
NL300352I2 (nl) 2008-11-03
EP0788511B1 (en) 2002-12-11
DK0788511T3 (da) 2003-03-31
CA2202058A1 (en) 1996-04-18
FI119988B (fi) 2009-05-29
BR9504791A (pt) 1996-10-22
US6265536B1 (en) 2001-07-24
CN1203089C (zh) 2005-05-25
TR199501229A2 (tr) 1996-07-21
MX9702531A (es) 1997-06-28
OA10475A (en) 2002-04-08
HK1004136A1 (en) 1998-11-20
IL115484A0 (en) 1996-01-19
RU2165423C2 (ru) 2001-04-20
DE69529172T2 (de) 2003-04-17
FR08C0028I2 (cg-RX-API-DMAC7.html) 2009-11-20
FI971397A0 (fi) 1997-04-04
HU228151B1 (en) 2012-12-28
AU3578095A (en) 1996-05-02
BRPI9504791B8 (pt) 2019-12-31
AR041770A1 (es) 2005-06-01
WO1996011210A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
BR9611184B8 (pt) Composto e composição.
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
FI944832A7 (fi) Farmaseuttinen koostumus
NO962606D0 (no) Farmasöytisk sammensetning
ITMI932540A0 (it) Composizione farmaceutica
BR9509688A (pt) Composto e composição farmacêutica
BR9507768A (pt) Composição farmacêutica
LV11727A (lv) Farmaceitiska kompozicija
ID18698A (id) Komposisi farmasi
FI973280A7 (fi) Farmaseuttinen koostumus
LV10579A (lv) Farmaceitiska kompozicija
FI961364L (fi) Lääkeainekoostumus
ITMI962628A0 (it) Composizione farmaceutica
BR9605777A (pt) Composição farmacêutica
BR9605131A (pt) Composição farmacêutica
BR9505130A (pt) Composto e composiçao farmacêutica
BR9507063A (pt) Peptídeo derivado de substituição de peptídeo e composição farmacêuticas
IT1272935B (it) Composizione farmaceutica contenente n-acetil-cisteina
BR1100691A (pt) Composto, e, composição farmacêutica
BR1101082A (pt) Composto, e, composição farmacêutica
BR1100310A (pt) Peptìdeo, composto e composição farmacêutica
BR9500539A (pt) Composto farmacêutico e composição farmacêutica
SE9402924D0 (sv) Novel pharmaceutical composition
BR1100960A (pt) Composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B15K Others concerning applications: alteration of classification

Free format text: ALTERACAO DE CLASSIFICACAO DE C07K 7/64, C07K 1/36, C07K103/00, C07M 7/00, C07M 9/00, A61K 38/08 PARA : C07K 7/56, A61K 38/12 O PRESENTE PEDIDO REFERE-SE A PEPTIDEOS CICLICOS APRESENTANDO UMA LIGACAO PEPTIDICA ANORMAL; E COMPOSICOES.

Ipc: C07K 7/56, A61K 38/12

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/10/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061162/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132252-414.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: ASTELLAS PHARMA INC., AVENTIS PHARMA S.A, BIOCREA GMBH, BRACCO S.P.A, CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2074 DE 05/10/2010 QUANTO A DATA DE VALIDADE CONFORME DETERMINADO NO INPI 52400.061162/2013 SECAO JUDICIARIA DO RIO DE JANEIRO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0001999-28.2014.4.02.5101.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061162/2013 SECAO JUDICIARIA DO RIO DE JANEIRO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0001999-28.2014.4.02.5101 APELANTE: ASTELLAS PHARMA INC.APELADO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: DEFIRO O REQUERIMENTO FORMULADO PELO INPI, DETERMINANDO A IMEDIATA CORRECAO DO PRAZO DE VIGENCIA DA PATENTE PI 9504791-3 PARA 05/10/2015.

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52400.061162/2013-38 NUP: 00408.030830/2018-16 (REF. 0001999-28.2014.4.02.5101) INTERESSADOS: INTERFARMA ASSOCIACAO DA INDUSTRIA FARMACEUTICA DE PESQUISA E OUTROS DECISAO: PELO EXPOSTO, DEFIRO O REQUERIMENTO FORMULADO PELO INPI, DETERMINANDO A IMEDIATA CORRECAO DO PRAZO DE VIGENCIA DA PATENTE PI9504791-3 PARA 06.10.2015.